NCT03298516View on ClinicalTrials.gov

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

DCLL9718S

DCLL9718S will be administered as per the schedule specified in the respective arm.

DRUG

Azacitidine

Azacitidine will be administered as per the schedule specified in the respective arm.

Trial Locations (8)

10032

Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

91010

City of Hope, Duarte

06510

Yale School of Medicine, New Haven

T6G 1C9

University of Alberta Hospital, Edmonton

M5G 2M9

Princess Margaret Hospital; Department of Med Oncology, Toronto

H3T 1E2

Jewish General Hospital / McGill University, Montreal

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03298516 - A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | Biotech Hunter | Biotech Hunter